KT502 not checked

Kali Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3”In the company’s words, NCT07564154 on ClinicalTrials.gov
Tested for
Rheumatoid Arthritis (RA)
Main trialPhase 1
“This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.”In the company’s words, NCT07564154 on ClinicalTrials.gov

Other drugs for Rheumatoid Arthritis (RA)

All 80 drugs for Rheumatoid Arthritis (RA)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Dec 2027 A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow KT502

Following is part of Solo: you see every change to KT502 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in